Tpbgl, or trophoblast glycoprotein-like, emerges as a pivotal player in cellular regulation, with its predicted function centered around the negative regulation of the canonical Wnt signaling pathway. This glycoprotein-like molecule is anticipated to function as an integral component of the plasma membrane, actively involved in modulating cellular responses to extracellular cues. The role of Tpbgl in negatively regulating canonical Wnt signaling implies its significance in balancing cellular processes influenced by this pathway. As an ortholog of the human TPBGL gene, Tpbgl likely shares conserved functions that contribute to the intricate regulatory network governing Wnt signaling. The activation of Tpbgl involves a sophisticated interplay of various chemical compounds, each influencing specific components or pathways related to the canonical Wnt signaling cascade. These mechanisms predominantly operate at the plasma membrane, where Tpbgl exerts its negative regulatory influence. GSK-3β inhibitors, for instance, impact the canonical Wnt pathway by altering the activity of GSK-3β, thereby indirectly up-regulating Tpbgl. Tankyrase inhibitors modulate β-catenin degradation, reinforcing the negative regulatory role of Tpbgl within the Wnt pathway. These chemical modulators collectively contribute to the suppression of canonical Wnt signaling at the plasma membrane, showcasing the adaptability and responsiveness of Tpbgl to external cues. The intricate network of activation mechanisms sheds light on Tpbgl's essential role in maintaining cellular homeostasis through fine-tuned regulation of canonical Wnt signaling, a process crucial for cellular development and function.
In summary, Tpbgl stands as a key orchestrator in cellular regulation, positioned at the plasma membrane to exert its influence on the canonical Wnt signaling pathway. Its activation is intricately governed by a diverse array of chemical modulators, each targeting specific components within the Wnt cascade. This glycoprotein-like molecule's negative regulatory role within the pathway underscores its importance in fine-tuning cellular responses to Wnt signaling, contributing to the overall balance and functionality of cellular processes. The understanding of Tpbgl's function and activation mechanisms provides valuable insights into the broader landscape of cellular regulation and the intricate interplay between proteins and signaling pathways in maintaining cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
GSK-3β inhibitor impacting Wnt signaling pathway, indirectly enhancing Tpbgl. Alters GSK-3β activity, contributing to negative regulation of canonical Wnt signaling at the plasma membrane. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
γ-Secretase inhibitor influencing Notch signaling, indirectly promoting Tpbgl function. Alters Notch pathway activity, contributing to the negative regulation of canonical Wnt signaling at the membrane. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
Tankyrase inhibitor affecting Wnt/β-catenin pathway, indirectly enhancing Tpbgl. Alters β-catenin degradation, contributing to negative regulation of canonical Wnt signaling at the plasma membrane. | ||||||
β-Catenin/Tcf Inhibitor, FH535 | 108409-83-2 | sc-221398 sc-221398A | 10 mg 50 mg | $182.00 $374.00 | 7 | |
β-Catenin/TCF inhibitor affecting Wnt/β-catenin pathway, indirectly promoting Tpbgl. Modulates β-catenin-TCF interaction, contributing to negative regulation of canonical Wnt signaling at the membrane. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $96.00 $292.00 | 27 | |
Porcupine inhibitor influencing Wnt secretion, indirectly enhancing Tpbgl. Alters Wnt ligand availability, contributing to negative regulation of canonical Wnt signaling at the plasma membrane. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
GSK-3 inhibitor affecting Wnt signaling, indirectly promoting Tpbgl. Alters GSK-3 activity, contributing to the negative regulation of canonical Wnt signaling at the plasma membrane. | ||||||
NSC 668036 | 144678-63-7 | sc-507412 | 5 mg | $175.00 | ||
Dvl PDZ domain inhibitor impacting Wnt signaling, indirectly enhancing Tpbgl. Alters Dvl function, contributing to negative regulation of canonical Wnt signaling at the plasma membrane. | ||||||
Cercosporin | 35082-49-6 | sc-255013 | 5 mg | $459.00 | 1 | |
Axin stabilizer affecting Wnt pathway, indirectly promoting Tpbgl function. Modulates Axin levels, contributing to negative regulation of canonical Wnt signaling at the plasma membrane. | ||||||
AZD1080 | 612487-72-6 | sc-503187 | 2.5 mg | $280.00 | ||
GSK-3 inhibitor affecting Wnt signaling, indirectly promoting Tpbgl. Alters GSK-3 activity, contributing to the negative regulation of canonical Wnt signaling at the plasma membrane. | ||||||
PKF118-310 | 84-82-2 | sc-364590 sc-364590A | 5 mg 25 mg | $180.00 $651.00 | ||
Dishevelled inhibitor impacting Wnt signaling, indirectly enhancing Tpbgl. Alters Dishevelled function, contributing to negative regulation of canonical Wnt signaling at the plasma membrane. | ||||||